Main trial design. . Double-blind. ACS (STEMI or UA/NSTEMI) and planned PCI. ASA. . PRASUGREL60 mg LD/ 10 mg MD. CLOPIDOGREL300 mg LD/ 75 mg MD. 1o end point: CV death, MI, stroke2o end point: Stent thrombosis Safety end points: TIMI major bleeds, life-threatening bleeds. Duration of ther
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.